ProResearch offers comprehensive research analysis based on insights from top Wall Street analysts. These articles will soon be accessible exclusively to InvestingPro subscribers....
BOSTON - Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX). experienced a decline for the third straight day, closing at $343.00, a 1.81% drop during Thursday's trading session....
LONDON - CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) have achieved a significant milestone with the UK's Medicines and Healthcare products Regulatory...
On Tuesday, the stock futures experienced a slight downturn after Neel Kashkari, a representative of the Federal Reserve Bank of Minneapolis, suggested that additional measures...
Investing.com - Vertex (NASDAQ: VRTX) reported third quarter EPS of $3.97, $0.05 better than the analyst estimate of $3.92. Revenue for the quarter came in at $2.48B versus the...
A look at the day ahead in U.S. and global markets from Mike Dolan After its best week of 2023 on optimism about peaking interest rates, Wall Street's S&P500 looks set to record...
Investors are set to navigate a busy week as numerous S&P 500 companies, including BioNTech (NASDAQ:BNTX), Constellation Energy, Celanese (NYSE:CE), Vertex Pharmaceuticals...
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency (EMA) has validated a Type II variation application to the Marketing Authorization for...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KAFTRIO®...